Q5172: Injection, filgrastim-laha (filkri), biosimilar, 1 microgram
Q5172 is a HCPCS Level II code for injection, filgrastim-laha (filkri), biosimilar, 1 microgram. It belongs to the Temporary Codes section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q5172
- Long descriptor
- Injection, filgrastim-laha (filkri), biosimilar, 1 microgram
- Short descriptor
- Inj, filkri, 1 mcg
- Added
- October 1, 2026
- BETOS
- O1E
- Pricing indicator
- 51: Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service: CMS's own analytic grouping.
Drugs.
Codes adjacent to Q5172
HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If Q5172 is not quite right, the correct code is very often within a few positions of it.
- Q5164Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg
- Q5165Injection, denosumab-mobz (oziltus), biosimilar, 1 mg
- Q5166Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg
- Q5167Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg
- Q5168Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg
- Q5169Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg
- Q5170Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg
- Q5171Injection, denosumab-mobz (boncresa), biosimilar, 1 mg
- Q5173Injection, denosumab-adet (ponlimsi), biosimilar, 1 mg
- Q9001Assessment by chaplain services
- Q9002Counseling, individual, by chaplain services
- Q9003Counseling, group, by chaplain services
- Q9004Department of veterans affairs whole health partner services
- Q9950Injection, sulfur hexafluoride lipid microspheres, per ml
- Q9951Low osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml
- Q9953Injection, iron-based magnetic resonance contrast agent, per ml